A biomarker panel predicts recurrence-free survival in ulcerated primary cutaneous melanoma.
BRAF
Ki67
TILs
prognosis
ulcerated primary melanoma
Journal
Acta oncologica (Stockholm, Sweden)
ISSN: 1651-226X
Titre abrégé: Acta Oncol
Pays: England
ID NLM: 8709065
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
pubmed:
26
10
2021
medline:
22
1
2022
entrez:
25
10
2021
Statut:
ppublish
Résumé
Ulceration is an independent adverse prognostic factor in cutaneous malignant melanoma (CMM). There is, however, a need for additional prognostic markers to identify patients with ulcerated stage I-II CMM who have a high-risk for recurrence. The aim of this study was to examine the prognostic impact of We have used a consecutive cohort consisting of 71 primary ulcerated CMM (T1b-T4b). Proportion of Thus, this panel of markers could be an interesting novel concept for predicting the clinical outcome in patients with high-risk stage I-II ulcerated CMM.
Sections du résumé
BACKGROUND
BACKGROUND
Ulceration is an independent adverse prognostic factor in cutaneous malignant melanoma (CMM). There is, however, a need for additional prognostic markers to identify patients with ulcerated stage I-II CMM who have a high-risk for recurrence. The aim of this study was to examine the prognostic impact of
MATERIAL AND METHODS
METHODS
We have used a consecutive cohort consisting of 71 primary ulcerated CMM (T1b-T4b).
RESULTS
RESULTS
Proportion of
CONCLUSION
CONCLUSIONS
Thus, this panel of markers could be an interesting novel concept for predicting the clinical outcome in patients with high-risk stage I-II ulcerated CMM.
Identifiants
pubmed: 34694198
doi: 10.1080/0284186X.2021.1989719
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM